Biologics Manufacturing Market Size to Reach USD 152.07 Billion by 2034 at a 16.57% CAGR from 2026 to 2034

Biologics manufacturing industry size is estimated at USD 38.25 billion in 2025 and forecasted to reach USD 152.07 billion in 2034 with a CAGR of 16.57%. Growth in the biologics manufacturing market is fueled by growing need for sophisticated biological drugs.

Key Statistics:

• Market Size (2025): USD 38.25 Billion
• Market Size (2034): USD 152.07 Billion
• CAGR (2026-2034): 16.57%
• Dominating Region: North America

Report Highlights:

• Monoclonal antibodies segment held a dominant position valued at 47.20% in 2025 due to strong demand for targeted therapies across multiple therapeutic areas.
• Single-use systems segment led the market with 32.00% share in 2025 driven by increasing adoption of flexible and cost-efficient manufacturing solutions.
• Vaccines segment is expected to grow at a CAGR of 15.61% supported by rising global immunization programs.
• North America dominated the market with 45.40% share in 2025 due to strong R&D investments and advanced manufacturing infrastructure.
• Key companies operating in the market include AbbVie Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Catalent, Inc., Celltrion Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., FUJIFILM Diosynth Biotechnologies, Johnson & Johnson, Lonza Group AG, Novartis AG, Pfizer Inc., Samsung Biologics Co., Ltd., and WuXi Biologics (Cayman) Inc.

What’s Included in Biologics Manufacturing Report?

The report provides a detailed overview of the biologics manufacturing market based on product and technology. It includes regional analysis, industry dynamics, and competitive landscape. The study also covers manufacturing processes, capacity expansion trends, and demand across key therapeutic areas.

What are Driving Factors and Emerging Trends of Biologics Manufacturing Market?

As per analysis, the market is expanding due to increasing focus on advanced therapies and growing pharmaceutical investments. Key growth factors include:

• Increase in Demand for Customized Treatments: Growing popularity of monoclonal antibodies and gene-based treatments has led to increasing demands for mass production of biologics.
• Rising Production Capacity: Many pharmaceutical firms are making huge investments in technology and infrastructure aimed at increasing production capacity.
• Growing Role of CMOs: CMOs have been playing an increasingly important role in meeting the demands of the growing market through flexible manufacturing capabilities.

These trends indicate a strong shift toward scalable and efficient biologics production systems.

Request a free sample copy or read the full market insights: Biologics Manufacturing Market Report

Which Key Segments are Driving Biologics Manufacturing Market?

By Product Analysis

Monoclonal antibodies segment accounted for the largest share in 2025 due to increasing approvals and expanding clinical pipelines in oncology and autoimmune diseases.

By Technology Analysis

Single-use systems segment dominated the market in 2025 driven by increasing preference for flexible manufacturing and reduced contamination risk.

Which is Dominating Region in Biologics Manufacturing Market?

North America: North America led the market due to strong investment in research and advanced biopharmaceutical infrastructure.

Asia Pacific: Asia Pacific is expected to grow at the fastest rate driven by increasing outsourcing activities and expansion of manufacturing capabilities.

Where is Biologics Manufacturing Market Headed?

According to analysis, the market is expected to witness steady expansion supported by increasing biologics demand, technological advancements in manufacturing processes, and rising investments in production capacity.

What Biologics Manufacturing Market Report Reveals?

• What is the global market size, growth trend, and CAGR for the biologics manufacturing market through 2034?
• What are the key factors driving the growth of the biologics manufacturing market?
• Which firms are dominant in the market for producing biologics, and what is their competitive position in the industry?
• How is rising demand for biologics impacting manufacturing capacity growth?
• What role do CDMOs play in shaping biologics manufacturing market growth?
• What are the key regional trends across North America, Europe, and Asia Pacific in the biologics manufacturing market?
• Where do new opportunities arise in the biologics manufacturing market?

Who are Major Biologics Manufacturing Market Contributors?

According to our study, a few firms are leading in the global market. The following are some of the major market contributors:

• AbbVie Inc.
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Catalent, Inc.
• Celltrion Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• FUJIFILM Diosynth Biotechnologies
• Johnson & Johnson
• Lonza Group AG
• Novartis AG
• Pfizer Inc.
• Samsung Biologics Co., Ltd.
• WuXi Biologics (Cayman) Inc.

Market Segments Covered

By Product Outlook (Revenue, USD Billion, 2021-2034)

• Vaccines
• Antibodies
• Cell Therapy

By Technology Outlook (Revenue, USD Billion, 2021-2034)

• Single-Use
• Upstream
• Downstream

By Regional Outlook (Revenue, USD Billion, 2021-2034)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherland
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Israel
  • Rest of Middle East & Africa